Nasdaq grants HCW Biologics extension to regain compliance by Dec 31, 2025

HCW Biologics Inc.

Nasdaq Hearings Panel granted extension to demonstrate compliance with Equity Rule by Dec 31, 2025, and all listing rules by Feb 16, 2026.
Company was non-compliant with Listing Rule 5550(b)(1) (minimum stockholders' equity) as of June 30, 2025.
Hearing held September 25, 2025; Panel considered Company's compliance plan.
Company must timely file Form 10-Q for Q3 and notify Nasdaq of significant events during exception period.
Panel may review its decision within 45 calendar days after written decision.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.